Sana Biotechnology, Inc. · Healthcare · Biotechnology
Scores & Status Key
AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$4.22
−$0.05 (−1.29%) 4:00 PM ET
After hours$4.13
−$0.09 (−2.02%) 1:59 AM ET
Prev closePrevC$4.27
OpenOpen$4.14
Day highHigh$4.26
Day lowLow$4.09
VolumeVol1,581,122
Avg volAvgVol2,174,218
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$1.12B
P/E ratio
-4.35
EPS
-0.97
Sector
Healthcare
AI report sections
MIXED
SANA
Sana Biotechnology, Inc.
No AI report section text found yet for this symbol.
Volume vs average
Intraday (cumulative)
0% (Near avg)
Vol/Avg: 1.00×
RSI
52.19(Neutral)
Neutral (40–60)
0255075100
MACD momentum
Intraday
+0.01 (Strong)
MACD: 0.01 Signal: -0.00
Short-Term
+0.05 (Strong)
MACD: -0.08 Signal: -0.12
Long-Term
+0.01 (Strong)
MACD: -0.11 Signal: -0.13
Intraday trend score
57.00
LOW37.00HIGH61.00
Latest news
SANA•12 articles•Positive: 2Neutral: 4Negative: 6
PositiveGlobeNewswire Inc.• Sana Biotechnology
Sana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic Stem Cells in Preclinical Models Using the Fusogen Platform
Sana Biotechnology published research in Nature Biotechnology demonstrating successful in vivo gene editing of human hematopoietic stem cells using fusogen technology, potentially transforming treatment for diseases like sickle cell and beta thalassemia without conditioning chemotherapy.
SANAgene editinghematopoietic stem cellsfusogen technologyin vivo deliveryCRISPR
Sentiment note
Published breakthrough research in a top-tier journal, demonstrated novel gene editing technology with potential transformative medical applications, and outlined clear development pathway for future treatments
PositiveBenzinga• Erica Kollmann
Sana Biotech Stock — The Next '100-Bagger'?
Stock promoter Eric Jackson highlighted Sana Biotechnology as a potential '100-bagger' stock, citing falling interest rates, cooling inflation, and biotech sector revival as key catalysts.
Quell Therapeutics has formed a Scientific Advisory Board comprising leading experts in immunology, T-regulatory cell biology, and autoimmune diseases to guide its innovative CAR-Treg cell therapy development.
Company mentioned through an executive's board membership, with no direct commentary on performance or strategic developments
NeutralBenzinga• Globe Newswire
Sana Biotechnology Announces Pricing of Public Offering
Sana Biotechnology has priced a public offering of 20,895,522 shares at $3.35 per share and pre-funded warrants, expecting to raise approximately $75 million. Morgan Stanley, Goldman Sachs, BofA Securities, and TD Cowen are joint book-running managers for the offering.
The company is raising capital through a standard public offering, which indicates a strategic financial move to fund operations without immediate positive or negative implications
NeutralGlobeNewswire Inc.• Nicole Keith
Sana Biotechnology Announces Pricing of Public Offering
Sana Biotechnology plans to raise approximately $75 million through a public offering of 20,895,522 common shares and pre-funded warrants at $3.35 per share, with Morgan Stanley, Goldman Sachs, BofA Securities, and TD Cowen as joint book-running managers.
The company is conducting a standard public offering to raise capital, which is a typical financial strategy for biotechnology firms seeking funding for research and development
NeutralGlobeNewswire Inc.• Mark Swallow, Sandi Greenwood
Draig Therapeutics Appoints Experienced Biotech Leader Douglas E. Williams, Ph.D. as Chair of its Board of Directors
Draig Therapeutics, a clinical-stage neuropsychiatric drug development company, appointed Douglas E. Williams, Ph.D. as independent Chair of its Board of Directors. Dr. Williams brings over 30 years of biotech leadership experience from companies like Biogen and Amgen.
BIIBAMGNSANAneuropsychiatryboard appointmentbiotech leadershipdrug development
Sentiment note
Mentioned as Dr. Williams' most recent role as President of R&D
NegativeBenzinga• Prnewswire
SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Sana Biotechnology, Inc. (SANA) is facing a securities fraud lawsuit alleging the company made false and misleading statements about its financial position and product pipeline, leading to investor losses.
SANASana Biotechnologysecurities fraudlawsuit
Sentiment note
The article alleges that Sana Biotechnology made false and misleading statements about its financial position and product pipeline, leading to investor losses. This suggests the company's actions were detrimental to investors.
NegativeGlobeNewswire Inc.• Faruqi & Faruqi, Llp
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana Biotechnology
Sana Biotechnology is facing a securities class action lawsuit alleging the company made false and misleading statements about its financial capacity and the prospects of its product candidates. The lawsuit claims Sana overstated its financial position and was likely to decrease funding or discontinue certain programs.
SANASana Biotechnologysecurities class actionfalse and misleading statementsfinancial capacityproduct candidates
Sentiment note
The article discusses a securities class action lawsuit against Sana Biotechnology, alleging the company made false and misleading statements about its financial position and the prospects of its product candidates. This suggests a negative sentiment towards the company.
NegativeBenzinga• Prnewswire
SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Sana Biotechnology, Inc. (SANA) is facing a securities fraud lawsuit alleging the company made false and misleading statements about its financial position and product pipeline.
SANASana Biotechnologysecurities fraudlawsuit
Sentiment note
The article states that Sana Biotechnology is facing a securities fraud lawsuit, alleging the company made false and misleading statements about its financial position and product pipeline, which led to investor losses.
NegativeGlobeNewswire Inc.• N/A
Faruqi & Faruqi Reminds Sana Biotechnology Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 - SANA
Faruqi & Faruqi, LLP is investigating potential claims against Sana Biotechnology, Inc. (SANA) for making false and/or misleading statements about its financial capacity and product candidates. The firm reminds investors of the May 20, 2025 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit against the company.
The article alleges that Sana Biotechnology made false and misleading statements about its financial capacity and the prospects of its product candidates, leading to significant stock price declines when the truth was revealed.
SANA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sana Biotechnology, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
A class action lawsuit has been filed against Sana Biotechnology, Inc. (SANA) alleging the company made materially false and misleading statements about its financial capacity, product candidates, and operations.
The article alleges that Sana Biotechnology made false and misleading statements about its financial capacity, product candidates, and operations, which led to substantial losses for investors.
NegativeBenzinga• Prnewswire
SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Sana Biotechnology, Inc. (SANA) is facing a securities fraud lawsuit alleging the company made false and misleading statements about its financial position and product pipeline, leading to investor losses.
SANASana Biotechnologysecurities fraudlawsuit
Sentiment note
The article alleges that Sana Biotechnology made false and misleading statements about its financial position and product pipeline, leading to investor losses. This suggests the company's actions were detrimental to investors.
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
